Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer
PURPOSE: Complete androgen blockade (CAB) does not prolong overall survival (OS) in patients with castration refractory prostate cancer (CRPC).Although there is variable clinical benefit with second-line hormone manipulation, we do not know which patients might benefit the most.OBJECTIVES: To identify clinical predictors of benefit of complete andr